Company Press Releases 31 Oct 2025 FLAG Therapeutics Secures Over $500,000 in Equity and Impact Funding from Venture and Mission-Driven Investors, Including Springhood Ventures, Kids Beating Cancer, The Musella Foundation, the AYJ Fund, Tough2gether Foundation and DDRFA 31 Jan 2023 FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG) 8 Aug 2017 FLAG Therapeutics Oversubscribes Financing Round and Receives $500,000 Matching Loan From North Carolina Biotechnology Center 29 Feb 2016 FLAG Therapeutics Granted Orphan Drug Designation for FLAG-003 for the Treatment of Glioma 16 Jul 2024 FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) FLAG in the News 17 Nov 2019 NEW PANCREATIC CANCER TREATMENT TARGETS ONLY TUMOR CELLS
